SteriMax Acquires Andone Pharmaceuticals, Expanding into Medical Device and Veterinary Markets

SteriMax Inc., a prominent player in the Canadian pharmaceutical sector, has successfully acquired Andone Pharmaceuticals Inc. for an undisclosed amount. The transaction, announced on June 30, 2026, marks a significant strategic move for SteriMax, as it aims to enhance its portfolio and expand into the medical device and veterinary markets. This acquisition positions SteriMax as one of the largest privately owned pharmaceutical companies in Canada, further solidifying its market presence.

Andone Pharmaceuticals, based in Oakville, Ontario, was founded by Jay Barat with a mission to streamline operational challenges faced by healthcare professionals, allowing them to focus more on patient care. The company has developed a diverse portfolio that includes pharmaceuticals, medical devices, and veterinary products, catering to various healthcare sectors. This diversification aligns well with SteriMax's existing offerings, particularly its injectable portfolio, and provides a robust platform for growth in the veterinary and medical device sectors.

The acquisition is expected to accelerate SteriMax's expansion into adjacent markets, leveraging Andone's established customer relationships and expertise. With Andone's founder Jay Barat joining SteriMax to lead the new business units, the integration of the two companies is anticipated to enhance innovation and customer service. SteriMax's President and CEO, Samir Acharya, emphasized the strategic importance of this acquisition, noting that it positions the combined entity to better serve healthcare providers across a broader spectrum of care.

The broader pharmaceutical and medical device sectors are experiencing dynamic growth, driven by increasing demand for innovative healthcare solutions. As healthcare providers seek to improve operational efficiencies and patient outcomes, companies that can offer comprehensive solutions are likely to gain a competitive edge. SteriMax's acquisition of Andone positions it well to capitalize on these trends, particularly in the veterinary and medical device markets, which are poised for expansion.

Overall, this acquisition underscores SteriMax's commitment to growth and innovation within the healthcare landscape. By integrating Andone Pharmaceuticals into its operations, SteriMax not only broadens its product offerings but also enhances its ability to meet the evolving needs of healthcare providers and patients alike. As the market continues to evolve, the combined strengths of SteriMax and Andone are expected to yield significant benefits, both for the companies involved and for the healthcare ecosystem as a whole.